Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2031-05-14
Target enrollment:
Participant gender:
Summary
This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.